Avexa Of Australia Reports Good Results With HIV Drug
This article was originally published in PharmAsia News
Australian drug maker Avexa reports positive results from a Phase II study of its apricitabine HIV drug to treat patients unresponsive to GlaxoSmithKline's Epivir (lamivudine). Avexa CEO Julian Chick said the study showed the firm's drug to be at least as good as the safest HIV drug on the market. The study reported the drug reduced the AIDS-causing virus to insignificant levels in 89 percent of patients. Avexa seeks to license marketing rights to a larger partner so it can complete the studies this year. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.